Bay Street News, December, 2018

Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapies PRECISION-AF, planned Phase 3 clinical […]

CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on […]

EL SEGUNDO, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) — Landmark Infrastructure Partners LP (the “Partnership”) (NASDAQ: LMRK) announced today that […]

SACRAMENTO, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) — Bank of Commerce Holdings (NASDAQ: BOCH), a $1.3 billion asset bank holding company […]

EMERYVILLE, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next […]

BURLINGTON, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) will announce preliminary unaudited revenue for the fourth-quarter […]

Planning for Phase 2 Clinical Trial Underway OTTAWA, Dec. 20, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) […]

WALDORF, Md., Dec. 20, 2018 (GLOBE NEWSWIRE) — The Community Financial Corporation (NASDAQ: TCFC) (the “Company”) announced today that its […]

MAYNARD, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) — AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company […]

VANCOUVER, British Columbia, Dec. 20, 2018 (GLOBE NEWSWIRE) — Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” […]